- Market Realist•yesterday
In Russia, Teva Pharmaceutical has created a strong portfolio of about 300 products and has been extensively developing its research pipeline.
- Capital Cube•2 days ago
Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Takeda Pharmaceutical Co., Ltd. Here are 5 ETF’s with the largest exposure to TKPYY-US. Comparing the performance and risk of Takeda Pharmaceutical Co., Ltd. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)
- PR Newswire•3 days agoAdditional Interim Data Supporting Long-Term Use of Vedolizumab in Patients with Ulcerative Colitis and Crohn's Disease Published in Journal of Crohn's and Colitis
OSAKA, Japan, Sept. 29, 2016 /PRNewswire/ -- Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") announced that two interim reports from the ongoing, open-label GEMINI long-term safety (LTS) study describing clinical data of long-term Entyvio (vedolizumab) treatment in patients with moderately to severely active ulcerative colitis (UC) and moderately to severely active Crohn's disease (CD) have been published in the Journal of Crohn's & Colitis. The data showed that patients with moderately to severely active UC experienced clinical and health-related quality of life (HRQL) improvements with continued vedolizumab treatment. For patients with moderately to severely active CD, the clinical benefits of vedolizumab continued with long-term treatment regardless of prior TNF antagonist exposure.
Takeda Pharmaceutical Company Limited (TKPYY)
Other OTC - Other OTC Delayed Price. Currency in USD
|Day's Range||23.59 - 24.12|
|52wk Range||20.32 - 25.72|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||24.52|
|Avg Vol (3m)||36,126|
|Dividend & Yield||0.87 (3.59%)|